CRL Charles River Laboratories International Inc.

Charles River Partners with JADE Biomedical to Expand Biologics Capabilities

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with , a provider of end-to-end quality management services for the biopharmaceutical industry. The partnership will expand Charles River’s biologics testing capabilities geographically and help to accommodate demand for biologics therapeutics, especially cell and gene therapies, reaffirming the company’s commitment as a global development partner. This strategic relationship will also enable JADE to expand their current global Good Manufacturing Practice (GMP) product testing operations in Shanghai into a second facility and further build upon its current offering of comprehensive biologics quality management and testing services.

This press release features multimedia. View the full release here:

As the biologics therapeutics industry across the globe continues to grow at a rapid pace, so does the demand for a reliable contract services partner. The recent growth in commercialization efforts in the cell and gene therapy market requires both scientific and regulatory expertise to navigate the complex, global regulatory environment. JADE’s deep understanding of global trends and the local environment, and its infrastructure designed to support clients of all sizes—from local start-ups to global organizations—makes it a highly valuable addition to Charles River’s network. The addition of a second testing facility, which will come online later this year, will provide additional capacity to better support clients’ growing needs. The new facility will offer GMP and Good Laboratory Practice (GLP) services to clients.

Approved Quotes

  • “Around the world, R&D efforts for cell and gene therapies are in high demand. Companies are seeking global partners who understand the complexities of this market, while also knowing how to navigate the nuanced regulatory environment in their region. Working with JADE, we will be able to combine our expertise to provide localized knowledge with a deep scientific and regulatory network, positioning both organizations as go-to partners for clients in this competitive market.” – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River
  • “JADE was founded with the purpose of serving the growing needs of the biopharmaceutical industry, not only in China, but internationally. JADE is a contracted Biologics Quality Organization, Bio-CQO R , where end-to-end quality and regulatory technical services are provided as an important addition to the biologics outsourced services industry, filling gaps in shortage of expertise and leadership in quality and compliance. We are extremely grateful to the conducive regulatory environment in recent years in China, and the trust of leading, global biopharmaceutical companies that have allowed us to form a unique service model and brand. To continue our growth in biologics therapeutics, especially in the gene and cell therapy space, we needed a partner with global reach. With an industry-leading portfolio of services and regulatory expertise, Charles River will help us support an increasing number of clients globally and locally.” – Claudia Lin, PhD, Founder and CEO, JADE Biomedical

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit .

About JADE Biomedical (JADE)

JADE Biomedical provides expert Quality, Regulatory and Analytical Testing Services to the Biopharmaceutical companies worldwide. It is the world’s first registered Biologics Contract Quality Organization, Bio-CQOR. JADE service portfolio includes Quality Assurance, Regulatory Submission, QC Method Validation and Testing, general CMC and Analytical Development, Facility Design and Qualification, Cold Chain Management, etc.. JADE founder and leaders have extensive drug regulatory experience with agencies including NMPA, FDA, EMA, PMDA and PICS. Our growing team of experts provide custom-made flexible yet robust Quality and CMC systems and lead their implementation in support of clients’ clinical and commercial programs from pre-IND to post-launch. JADE Biomedical contract testing services offer a complete range of analytical testing services suitable for global regulatory filings in our state of the art, global cGMP compliant labs. Our expertise covers all therapeutics platforms including monoclonal antibodies, Antibody-drug-conjugates, cell and gene therapies. To learn more about JADE and for current open positions, visit

EN
14/01/2021

Underlying

Reports on Charles River Laboratories International Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 18 March 2025 in which we reassessed the appropriateness of the rati...

 PRESS RELEASE

Charles River Laboratories to Present at Barclays Global Healthcare Co...

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, at 9:30 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends. A live webcast of the presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at . A webcast replay will be accessible through the same website after the presentation and will rem...

 PRESS RELEASE

Charles River Announces Agreement with Singapore General Hospital

WILMINGTON, Mass.--(BUSINESS WIRE)-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced an agreement with Singapore General Hospital (SGH) to provide Current Good Manufacturing Practice (CGMP) -compliant master cell banking (MCB) and next-generation sequencing (NGS)-based services for use in cell line characterization. SGH will use cord blood to derive and manufacture allogeneic chimeric antigen receptor (CAR) T-cells which will be used to treat patients with cancer. “We are thrilled to leverage our cell line characterization services and comprehensive NGS testing app...

Charles River Laboratories International Inc: 3 directors

Three Directors at Charles River Laboratories International Inc bought/sold/sold after exercising options 11,989 shares at between 162.500USD and 165.010USD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart whi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch